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Take home message: This study tested the use of scheduled intra-patient dose 
escalation to enhance the clinical benefit of sorafenib in patients with renal cell 
carcinoma. Patients who tolerated this approach exhibited better outcomes than 
those who didn’t, but relatively few patients could maintain doses higher than 
standard. 
Patient summary: This study tested a strategy of increasing the daily dose of 
sorafenib according to a planned schedule for treatment of advanced kidney cancer, 
but allowing for reductions and delays in treatment to help manage side effects. We 
found that disease outcomes showed apparent improvement for those patients who 
could tolerate an increase in dose over time . However, many patients were unable to 
tolerate the higher doses due to side effects of the treatment. We conclude that this 
strategy may benefit some, but should not be recommended for all patients. 
Trial registration: This clinical trial was registered with clinicaltrials.gov 
(NCT00618982). 
Keywords: renal cell carcinoma, sorafenib, dose escalation, targeted therapy, 
tyrosine kinase inhibitor 
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Abstract 
Background: Intra-patient dose escalation is a strategy which may enhance the 
clinical benefit of targeted anticancer agents in metastatic disease. 
Objective: To assess the efficacy and safety of sorafenib dose escalation in patients 
with metastatic renal cell carcinoma (mRCC) 
Design, setting, and participants: This non-randomized open-label Phase 2b study 
assessed sorafenib dose escalation in treatment-naïve patients with mRCC. 
Intervention: Patients initially received the standard dose of 400 mg BID oral 
sorafenib. Two dose escalations in 200 mg BID increments were planned, each after 
28 days at the prior level. Dose was reduced, interrupted, or dose escalation delayed 
to manage adverse events (AEs). 
Outcome measurements and statistical analysis: The primary endpoint was 
objective tumour response rate (ORR) in the modified intent-to-treat (ITT) population, 
which comprised patients with ≥6 months of treatment including ≥4 months of therapy 
at their highest tolerated dose. Secondary endpoints included progression-free 
survival (PFS) and safety. 
Results and limitation: 83 patients received sorafenib. The dose received for the 
longest duration was 400 mg BID in 48.2% patients; 600 mg BID in 15.7% patients; 
800 mg BID in 24.1% patients. ORR in the modified ITT population was 44.0% 
(n=8/18; 95% CI, 21.5–69.2); ORR in the ITT population was 17.9% (n=12/67; 95% 
CI, 9.6−29.2). Median PFS was 7.4 months (95% CI, 5.5‒11.5) in the ITT population. 
The most common AEs of any grade were hand–foot skin reaction (66.3%) diarrhoea 
(63.9%), rash/desquamation (56.6%) and fatigue (54.2%). 
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Conclusions: Sorafenib demonstrated clinical benefit in treatment-naïve patients 
with mRCC. However, relatively few patients could sustain doses above 400 mg BID. 
There was evidence that where tolerated, escalation from the standard sorafenib 
dose may have provided enhanced clinical benefit. However, this study does not 
support dose-escalation for most patients with treatment-naïve mRCC. Alternative 
protocols for sorafenib dose escalation could be explored. 
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1. Introduction 
The advent of molecularly targeted agents brought welcome advances in the 
treatment of patients with metastatic renal cell carcinoma (mRCC). However, more 
effective approaches to this ultimately intractable disease are needed. One strategy 
is intra-patient dose escalation of agents that have demonstrated efficacy and 
tolerability.  
Sorafenib, an oral inhibitor of several kinases involved in tumour angiogenesis and 
cell proliferation, is approved in differentiated thyroid carcinoma, hepatocellular 
carcinoma and advanced/metastatic renal cell carcinoma (RCC) [1-6]. The pivotal 
TARGET trial demonstrated efficacy of sorafenib 400 mg twice daily (BID), which 
subsequently became the approved regimen [3-6]. 
In attempts to enhance clinical outcomes, doses of sorafenib higher than 400 mg BID 
have been investigated [7-9]. In a Phase 2 study of patients with mRCC, half of 
whom had received prior systemic therapy, the sorafenib dose was escalated at 
monthly intervals to 600 mg BID, then 800 mg BID [9]. Of the 44 patients evaluable 
for response, 70.5% received a dose escalation to 800 mg BID sorafenib; objective 
response rate (ORR) was 47.7%, and median PFS was 8.4 months [9]. These 
outcomes compared favourably with those of the TARGET study. 
In light of these results, further investigation of sorafenib dose escalation was 
warranted. Here we report efficacy, safety and tolerability outcomes from an open-
label Phase 2b study of planned sorafenib dose escalation in treatment-naïve 
patients with mRCC.  
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2. Patients and methods 
2.1. Study design and patients 
This was a non-randomized, open-label, uncontrolled, multicentre Phase 2b study 
(ClinicalTrials.gov NCT00618982). Eligible patients (aged ≥18 years) had 
histologically or cytologically confirmed metastatic clear cell RCC, with no prior 
systemic therapy for RCC; Eastern Cooperative Oncology Group performance status 
0 or 1; intermediate or good prognosis according to the Memorial Sloan-Kettering 
Cancer Center scale; at least one measurable lesion by CT scan or MRI according to 
RECIST v1.0; life expectancy ≥12 weeks; prior total nephrectomy; and adequate 
bone marrow, liver, and renal function assessed within 7 days prior to study 
treatment. Prior palliative radiotherapy to metastatic lesions was permitted. 
Exclusion criteria were: history of cardiac disease (congestive heart failure 
>New York Heart Association class 2; acute coronary disease [myocardial infarction 
>6 months before study entry was allowed]; cardiac arrhythmias requiring 
anti-arrhythmic therapy [beta-blockers or digoxin were permitted]; or uncontrolled 
hypertension); history of HIV infection or chronic hepatitis B or C; active clinically 
serious infections >grade 2; symptomatic metastatic brain or meningeal tumours; 
seizure disorders requiring medication; history of organ allograft; evidence or history 
of bleeding diathesis; deep vein thrombosis and/or pulmonary embolus within 
12 months of treatment initiation; delayed healing of wounds, ulcers or bone 
fractures; pre-existing thyroid abnormality; undergoing renal dialysis; previous or 
concurrent cancer distinct in primary site or histology from cancer being evaluated in 
this trial [except cervical carcinoma in situ, treated basal cell carcinoma, superficial 
bladder tumours or any cancer curatively treated ≥3 years prior to study entry]; 
pregnancy/breastfeeding; inability to swallow oral medications; any prior systemic 
anticancer therapy; major surgery within 4 weeks prior to study entry; radiotherapy 
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within 3 weeks of study drug initiation; biologic response modifiers, eg granulocyte 
colony stimulating factor (G-CSF), within 3 weeks prior to study entry; or autologous 
bone marrow transplant or stem cell rescue within 4 months of study. 
All patients provided written informed consent and study approval was obtained from 
ethics committees. The study was conducted in accordance with the World Medical 
Association (WMA) Declaration of Helsinki, the International Conference on 
Harmonization (ICH) guideline E6 for Good Clinical Practice, and local ethical and 
legal requirements. 
2.2. Treatment 
Patients received initial treatment with oral sorafenib 400 mg BID. Two dose 
escalations were planned: to 600 mg BID after 28 days at the starting dose, then to 
800 mg BID after a further 28 days. However, if a patient developed any symptomatic 
AE ≥grade 3, except for nausea or vomiting, no dose escalation was allowed until the 
event resolved to at least grade 1. Treatment was maintained at the highest tolerated 
dose until disease progression, unacceptable toxicity, withdrawal of consent, 
investigator’s decision, or study end. Dose delays or reductions to 400 mg daily or 
alternate days could be used to manage AEs. Specific criteria were defined for dose 
modification or delay due to dermatologic AEs, hypertension, hematologic AEs, and 
non-hematologic AEs (Supplementary Tables 1–5). 
Concomitant therapies were allowed as follows: palliative radiotherapy to ≤10% of 
the patient’s bone marrow provided a target lesion was not irradiated and there was 
no progressive disease; G-CSF and other haemopoeitic growth factors to manage 
acute toxicity and secondary (but not primary) prophylaxis with erythropoietin, 
providing these did not replace a required sorafenib dose reduction; or other 
palliative and supportive care, including bisphosphonates.  
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2.3. Assessments 
Efficacy analyses were performed in the intention-to-treat (ITT) population, defined 
as all patients who received at least one sorafenib dose and had at least one valid 
efficacy evaluation post-baseline. For analysis of the primary endpoint, the modified 
ITT (mITT) population was defined as the subgroup of patients treated for at ≥6 
months with ≥4 months at their highest tolerated sorafenib dose. Safety analyses 
were performed in all patients who received at least one sorafenib dose and for 
whom data were available after baseline.  
The primary endpoint was ORR (complete or partial response) at 6 months in 
patients with ≥4 months of therapy at the highest tolerated dose. Secondary 
endpoints included PFS, disease control rate (DCR; complete or partial response, or 
stable disease), time to progression (TTP), safety and tolerability, and 
pharmacokinetics. 
Tumour response and progression were assessed by central, independent, 
radiological review every 8 weeks using Response Evaluation Criteria in Solid 
Tumors (RECIST) v1.0 [10]. Objective responses or stable disease were confirmed 
at the next scheduled scan. PFS was assessed from the start of study medication to 
the first radiological or clinical progression, or death. TTP was measured from the 
start of study medication to the first radiological or clinical progression. AEs were 
assessed according to the National Cancer Institute’s Common Terminology Criteria 
for Adverse Events (NCI-CTCAE) v3.0 [11]. Pharmacokinetic samples (6 mL) were 
collected on day 28 of the first completed cycle at each dose level at the following 
time points: pre-dose and 2, 4, 6, 8, 10 and 12 hours post-dose. Plasma levels of 
sorafenib and its metabolites (M2, M4, and M5) were measured to investigate the 
relationship between dose level and drug exposure. 
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2.4. Statistical analyses 
No formal sample size calculation was required as this was an open-label study. The 
sample size was based on the width of the 95% confidence interval (CI) of the ORR, 
which would not exceed ±11% with a sample size of 80 patients. 
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3. Results 
3.1. Patients 
The first patient was treated on February, 04, 2008; the last visit of the last patient 
was January, 13, 2011. 89 patients were enrolled overall at 19 centres in France, UK, 
Germany, Italy, and Poland. Of these, 83 patients were treated with sorafenib and 
included in the safety population (Supplementary Figure 1).The ITT and mITT 
populations included 67 and 18 patients, respectively. Most of the ITT population 
excluded from the mITT analysis set discontinued sorafenib due to disease 
progression (Supplementary Table 6). Most patients in the safety population had 
more than one metastatic lesion (83.1%); the most frequent site of metastasis was 
lung (63.9% of patients) [Table 1].  
Analysis of patients grouped by sorafenib dose received for the longest duration 
showed similar baseline demographics, although a higher proportion of patients had 
bone metastases in the 400 mg BID dose group compared with other groups 
(36.0%,16.7 %, and 15.0% in the 400, 600, and 800 mg BID dose groups, 
respectively). Mean time since diagnosis was 2.0, 0.7 and 2.3 years in the 400, 600 
and 800 mg BID dose groups, respectively. 
3.2. Treatment duration and doses received 
Median treatment duration in the safety population was 225 days (range 7‒1072 
days) and mean (standard deviation) daily dose was 902 (364) mg/day. The median 
duration of follow-up in the safety population was 252 days (range 14–1071 days). 
Of the 83 patients in the safety population, the maximum dose reached was 400 mg 
BID in 31 (37.3%) patients, 600 mg BID in 12 (14.5%) patients, and 800 mg BID in 
40 (48.2%) patients. Almost half of patients (n=40; 48.2%) received 400 mg BID for 
the longest duration (median duration [range], 29.5 days [7–855]), 20 patients 
13 
(24.1%) received 800 mg BID (177.5 days [56–956]), 13 patients (15.7%) received 
600 mg BID (164 days [62–681]), 7 patients (8.4%) received 400 mg daily (434 days 
[122–764]), and 3 patients (3.6%) were on 400 mg every other day (332 days [136–
675]) 
3.3. Efficacy 
In the mITT population, all patients showed partial response (n=8/18) or stable 
disease (n=10/18). The primary efficacy endpoint, ORR, was 44.4% (95% CI 21.5–
69.2%), and DCR was 100%. In the ITT population, ORR was 17.9% (n=12/67) [95% 
CI: 9.6‒29.2%], and DCR was 86.6% (n=58/67) and (Table 2).. Tumour shrinkage 
assessed in independent central review was seen in 72%, 75%, and 85% of patients 
in the 400, 600, and 800 mg BID dose groups, respectively (Figure 2). 
In the ITT population, median PFS was 7.4 months (95% CI: 6.0‒11.7) overall 
(Table 2 and Figure 1). The percentage of patients who were progression-free was 
62.3% at 6 months and 33.4% at one year. Median PFS was 3.7 (95% CI, 1.8–9.7 
months) months, 7.4 (6.3–12.0) months, and 8.5 (5.6–14.9) months, respectively, for 
the groups that received 400 mg BID, 600 mg BID, and 800 mg BID for the longest 
period during the study. The findings for TTP were identical to those for PFS, 
because no deaths occurred before disease progression was observed.  
3.4. Safety 
All patients reported at least one treatment-emergent adverse event (TEAE). The 
most common TEAEs of any grade were hand–foot skin reaction (HFSR; 66.3%) 
diarrhoea (63.9%), rash/desquamation (56.6%), fatigue (54.2%) and hypertension 
(48.2%) [Table 3]. Most patients (90.4%) experienced at least one ≥grade 3 event. 
The most common grade 3 events were HFSR (25.3%), fatigue (15.7%), 
hypophosphataemia (15.7%) and rash/desquamation (13.3%) [Table 3]. Apart from 
hyponatraemia and elevated lipase (both n=2 [2.4%]), grade 4 events occurred in 
14 
individual patients only. Table 4 summarizes TEAEs by dose at first occurrence. Most 
patients (91.6%) experienced their first AE at a dose of 400 mg BID.  
In the overall safety population, serious TEAEs were reported in 44 (53.0%) patients 
and most were single occurrences. The most common serious TEAEs, each 
occurring in 3 (3.6%) patients, were fatigue, rash/desquamation, and hyponatraemia.  
Dose interruptions, reductions, and withdrawals due to AEs occurred in 69 (83.1%), 
50 (60.2%) and 36 (43.4%) patients, respectively in the overall safety population. 
Dose interruptions or withdrawals occurred most frequently in patients receiving 
400 mg BID compared with the other doses. 
One death was reported, due to cardiopulmonary failure, which was not considered 
to be related to sorafenib. Another death was reported more than 30 days after the 
last study drug dose due to cardiopulmonary failure caused by progressive RCC. In 
both cases, the sorafenib dose that had been received for the longest duration was 
400 mg BID. 
3.5. Pharmacokinetics 
The pharmacokinetics of sorafenib and its metabolites (M2, M4, and M5) were 
assessed after 28 days of continuous oral administration of 400 mg, 600 mg, or 
800 mg BID. No increase in exposure (AUC or Cmax) was observed with the increase 
in dose, indicating a lack of dose proportionality (Supplementary Table 7). 
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4. Discussion 
In this open-label dose-escalation study, sorafenib showed clinical benefit in ORR, 
disease control rate, and PFS in treatment-naïve patients with mRCC.  
In the ITT population, median PFS (7.4 months) and ORR (17.9%) fell within the 
ranges reported in phase 2/3 studies of first-line standard-dose sorafenib in mRCC 
(mPFS: 5.7–9.1 months; ORR, 5.2%–30.0%) [3,8,12-16]. These data do not 
therefore support dose escalation as a strategy for all patients in this setting. When 
ORR and PFS in different dose groups are compared, patients who tolerated higher 
doses of sorafenib (>400 mg BID) appear to have experienced enhanced clinical 
benefit compared with those receiving doses ≤400 mg BID. However, meaningful 
comparison between the dosage groups is limited because this small, non-
randomized, uncontrolled study was not designed to explore this 
The ORR for the mITT population (44.4%) compares favourably to other first-line 
sorafenib trials [3,8,12-16], and is similar to that in the Phase 2 dose-escalation study 
of Amato et al (47.7%) [9]. Although clinical trials cannot be directly compared, these 
observation suggest that mITT patients may have gained additional benefit from 
sorafenib dose escalation compared with the standard treatment. A number of 
patients were excluded from the mITT either because they received sorafenib for less 
than 6 months, or were not treated for 4 months at their maximum tolerated dose. 
Therefore patients who tolerated sorafenib well, and those whose disease responded 
better to sorafenib may be over-represented in the mITT population. 
Outcomes in the ITT population appeared inferior to those reported by Amato and co-
workers who followed a similar dose-escalation protocol. This may reflect the fact 
that sorafenib therapy and dose escalation were less well tolerated in this study. Of 
note, the numbers of grade 3/4 AEs in the Amato study were much lower, allowing a 
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greater proportion of patients to reach and potentially benefit from the 800 mg BID 
dose [9].  
The pharmacokinetic analysis showed no apparent increase in sorafenib exposure at 
higher doses. However, patients were not randomized into dose groups, there is 
large inter-patient variation in sorafenib exposure at the same dose and incidence of 
grade 3/4 AEs has been associated with higher exposure [17]. Patients with low 
sorafenib exposure may therefore have been over-represented in the high-dose 
groups, being less prone to severe AEs that precluded dose escalation. Further 
confounding interpretation of pharmacokinetic data, samples from patients receiving 
higher doses were taken later than lower-dose samples, and sorafenib exposure 
declines over time [17,18]. 
No new or unexpected toxicities arose in our study. Most TEAEs first occurred with 
the starting dose of sorafenib, 400 mg BID which is consistent with previous analyses 
showing that AEs with sorafenib tend to first occur early in treatment [17]. 
Gastrointestinal disorders were the exception, most often starting with 600 or 800 mg 
BID. Again interpretation is difficult with respect to dose groups, but these findings 
are consistent with data from a sorafenib dose escalation study in metastatic 
melanoma, where HFSR and hypertension correlated with exposure, whereas 
diarrhoea and anorexia correlated with dose level [18]. The small proportion of 
patients (24%) who could sustain the highest dose level and the need for frequent 
dose reductions and interruptions to manage adverse events, reflect the difficulties of 
generally implementing a dose escalation schedule in this patient population. 
However, there may be value in exploring alternative protocols for sorafenib dose 
escalation, eg escalation to restore antitumour activity in patients whose disease 
progressed with reduced exposure, or regular monitoring of plasma concentrations 
and dose adjustment to maintain exposure over time [19,20].  
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5. Conclusions 
Escalating sorafenib dose from the standard level of 400 mg BID may have benefited 
individual patients who were able to tolerate this approach. However, this study does 
not support a scheduled dose-escalation strategy of this type for all patients with 
treatment-naïve mRCC. Alternative protocols for sorafenib dose escalation could be 
explored. 
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Tables and figures 
Table 1. Baseline demographic and clinical characteristics 
 Safety  
population 
ITT  
population 
 Overall 
(n=83) 
Overall 
(n=67) 
400 mg 
BIDa  
(n=25) 
600 mg 
BIDa  
(n=12) 
800 mg 
BIDa  
(n=20) 
Median (range) age, years 61 (33-80) 62 (33-80) 64 (44-80) 59 (33-78 57 (39-72) 
Male, n (%) 54 (65.1) 44 (65.7) 15 (60.0)  9 (75.0) 
 
15 (75.0) 
ECOG PS, n (%)      
0 49 (59.0) 40 (59.7) 14 (56.0)  7 (58.3) 13 (65.0) 
1 34 (41.0) 27 (40.3) 11 (44.0)  5 (41.7)  7 (35.0) 
Disease stage, n (%)      
III 1 (1.2) 1 (1.5) 0 0 0 
IV 82 (98.8) 66 (98.5) 25 (100.0) 12 (100.0) 20 (100.0) 
Clinical/radiological status      
Stable disease 15 (18.1) 12 (17.9)  4 (16.0)  2 (16.7)  2 (10.0) 
Progressive disease 68 (81.9) 55 (82.1) 21 (84.0) 10 (83.3) 18 (90.0) 
Mean (SD) time since initial 
diagnosisb, years 
2.1 (3.1) 2.0 (3.1) 2.0 (3.1) 0.7 (0.7) 2.3 (3.0) 
Number of metastatic sites, 
n (%) 
     
1 14 (16.9) 0 0 0 0 
≥2 69 (83.1) 67 (100) 25 (100.0) 12 (100.0) 20 (100.0) 
Metastatic sites, n (%)      
Lung 53 (63.9) 51 (76.1) 20 (80.0) 11 (91.7) 14 (70.0) 
Lymph nodes 33 (39.8) 33 (49.3) 10 (40.0)  7 (58.3) 11 (55.0) 
Liver 25 (30.1) 25 (37.3)  8 (32.0)  4 (33.3)  9 (45.0) 
Bone 16 (19.3) 16 (23.9)  9 (36.0)  2 (16.7)  3 (15.0) 
22 
Prior therapy for RCC, n (%)       
Surgery 83 (100.0) 67 (100.0) 25 (100.0) 12 (100.0) 20 (100.0) 
Radiotherapy 12 (14.5) 10 (14.9)  4 (16.0) 3 (25.0) 1 (5.0) 
Systemic anticancer 
therapy 
 3 (3.6)  2 (3.0)  1 (4.0)  0 (0.0) 0 (0.0) 
BID, twice daily; ECOG, Eastern Cooperative Oncology Group; ITT, intention-to-treat; 
PS, performance status; RCC, renal cell carcinoma; SD, standard deviation 
aDose taken for the longest time period while in the study; ten patients treated at doses <400 
mg BID are not included because of small sample sizes 
bThese data were unavailable for one patient in each of the overall safety population, the 
overall ITT population, and the 400 mg BID group 
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Table 2a. Tumour response and progression-free survival in the mITT population 
 Overall 
(n=18) 
400 mg 
QODa  
(n=2) 
400 mg 
once-dailya 
(n=5) 
400 mg 
BIDa 
(n=1) 
600 mg 
BIDa 
(n=2) 
800 mg 
BIDa 
(n=8) 
Partial response, n (%) 8 (44.4) 0 2 (40.0) 1 (100.0) 1 (50.0) 4 (50.0) 
Stable disease, n (%) 10 (55.6) 2 (100.0) 3 (60.0) 0 1 (50.0) 4 (50.0) 
Progressive disease, n (%) 0 0 0 0 0 0 
Response rate†, % (95% CI) 
44.4 
(21.5−69.2) 
0 
(0−84.2) 
40.0 
(5.3−85.3) 
100.0 
(2.5−100.0) 
50.0 
(1.3−98.7) 
50.0 
(15.7−84.3) 
Disease control rate‡, % (95% CI) 
100.0 
(81.5−100.0) 
100 
(15.8−100.0) 
100 
(47.8−100.0) 
100 
(2.5−100.0) 
100 
(15.8−100.0) 
100 
(63.1−100.0) 
BID, twice daily; CI, confidence internal; ITT, intention-to-treat; mITT, modified ITT; ND, not determined; PFS, progression-free survival; QOD, every other day 
No complete responses were recorded 
adose taken for the longest time period while in the study 
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Table 2b. Tumour response and progression-free survival in the ITT population 
 Overall 
(n=67) 
400 mg 
QODa  
(n=3) 
400 mg 
once-dailya 
(n=7) 
400 mg 
BIDa 
(n=25) 
600 mg 
BIDa 
(n=12) 
800 mg 
BIDa 
(n=20) 
Partial response, n (%) 12 (17.9) 0 2 (28.6) 1 (4.0) 2 (16.7) 7 (35.0) 
Stable disease, n (%) 46 (68.7) 3 (100) 5 (71.4) 15 (60.0) 10 (83.3) 13 (65.0) 
Progressive disease, n (%) 9 (13.4) 0 0 9 (36.0) 0 0 
Response rateb, % (95% CI) 
17.9 
(9.6−29.2) 
0 
(0–70.8) 
28.6 
(3.7–71.0) 
4.0 
(0.1−20.4) 
16.7 
(2.1−48.4) 
35.0 
(15.4−59.2) 
Disease control ratec, % (95% CI) 
86.6 
(76−93.7) 
100 
(29.2–100) 
100 
(59.0–100) 
64.0 
(42.5−82.0) 
100 
(73.5−100.0) 
100 
(83.2−100.0) 
Median (95% CI) PFS, months  
7.4 (5.5‒
11.5) 
NDd NDd 
3.7 
(1.8‒9.7) 
7.4 (6.3‒
12.0) 
8.5 (5.6‒
14.9) 
Progression-free at 6 months, % 55.3 NDd NDd 49.1 75.0 58.6 
Progression-free at 12 months, % 34.6 NDd NDd 24.6 22.2 39.1 
BID, twice daily; CI, confidence internal; ITT, intention-to-treat; mITT, modified ITT; ND, not determined; PFS, progression-free survival; QOD, every other day 
No complete responses were recorded 
adose taken for the longest time period while in the study 
bResponse rate defined as complete response + partial response 
cDisease control rate defined as complete response + partial response + stable disease 
dThese data were not determined due to the small sample sizes for these subgroups 
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Table 3. Incidences of treatment-emergent adverse events by worst grade, occurring 
in >10% patients at any grade, >5% patients at grade 3, or >2% patients at grade 4 
(safety population, N=83), n (%)  
Adverse event Any grade Grade 3 Grade 4 
Any event 83 (100.0%) 61 (73.5%) 13 (15.7%) 
Hand–foot skin reaction 55 (66.3%) 21 (25.3%) 0 
Diarrhoea 53 (63.9%) 10 (12%) 1 (1.2%) 
Rash/desquamation 47 (56.6%) 11 (13.3%) 0 
Fatigue 45 (54.2%) 13 (15.7%) 1 (1.2%) 
Hypertension 40 (48.2%) 5 (6.0%) 0 
Alopecia 36 (43.4%) 0 0 
Mucositis (functional/ symptomatic), oral cavity 27 (32.5%) 0 0 
Dry skin 23 (27.7%) 1 (1.2%) 0 
Nausea 22 (26.5%) 0 0 
Anorexia 21 (25.3%) 1 (1.2%) 0 
Hypophosphataemia 17 (20.5%) 13 (15.7%) 1 (1.2%) 
Vomiting 16 (19.3%) 1 (1.2%) 0 
Pruritus 15 (18.1%) 1 (1.2%) 0 
Fever 14 (16.9%) 0 0 
Weight loss 14 (16.9%) 1 (1.2%) 0 
Dyspnoea (shortness of breath) 13 (15.7%) 1 (1.2%) 0 
Haemoglobin 12 (14.5%) 1 (1.2%) 0 
Hypothyroidism 12 (14.5%) 0 0 
Neuropathy: sensory 12 (14.5%) 0 0 
Pain, abdomen not otherwise specified 11 (13.3%) 1 (1.2%) 0 
Taste alteration 11 (13.3%) 0 0 
Voice changes 11 (13.3%) 0 0 
Lipase 10 (12.0%) 10 (12.0%) 2 (2.4%) 
Pain, back 10 (12%) 3 (3.6%) 0 
Alanine aminotransferase 7 (8.4%) 5 (6%) 0 
Hyponatraemia 5 (6%) 3 (3.6%) 2 (2.4%) 
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Table 4. Incidences of treatment-emergent adverse events (any grade, occurring in 
>10% of patients in any category) by dose at first occurrence (safety population), 
n (%)  
Adverse event 
400 mg 
QOD 
n=10 
400 mg 
OD 
n=38 
400 mg 
BID 
n=83 
600 mg 
BID 
n=52 
800 mg 
BID 
n=40 
Any event 1 (10.0) 5 (13.2) 76 (91.6) 0 1 (2.5) 
Hypertension 2 (20.0) 4 (10.5) 29 (34.9) 2 (3.8) 2 (5.0) 
Fatigue 2 (20.0) 2 (5.3) 29 (34.9) 4 (7.7) 5 (12.5) 
Weight loss 0 0 5 (6.0) 2 (3.8) 7 (17.5) 
Alopecia 1 (10.0) 5 (13.2) 16 (19.3) 9 (17.3) 5 (12.5) 
Dry skin 1 (10.0) 1 (2.6) 13 (15.7) 3 (5.8) 5 (12.5) 
Hand–foot skin reaction 0 3 (7.9) 43 (51.8) 5 (9.6) 4 (10.0) 
Pruritus 0 2 (5.3) 10 (12.0) 2 (3.8) 0 
Rash/desquamation 1 (10.0) 1 (2.6) 38 (45.8) 5 (9.6) 2 (5.0) 
Anorexia 1 (10.0) 0 6 (7.2) 8 (15.4) 6 (15.0) 
Diarrhoea 1 (10.0) 3 (7.9) 21 (25.3) 19 (36.5) 9 (22.5) 
Oral mucositis 
(functional/symptomatic) 
1 (10.0) 2 (5.3) 19 (22.9) 4 (7.7) 1 (2.5) 
Nausea 2 (20.0) 2 (5.3) 10 (12.0) 3 (5.8) 5 (12.5) 
Vomiting 0 1 (2.6) 8 (9.6) 2 (3.8) 5 (12.5) 
Hypocalcaemia 0 0 1 (1.2) 0 5 (12.5) 
Hypophosphataemia 0 1 (2.6) 13 (15.7) 3 (5.8) 0 
BID, twice daily; NOS, not otherwise specified; OD, once daily; QOD, every other day.   
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Figure 1. Kaplan-Meier graph showing progression-free survival by independent 
central assessment according to the dose received for the longest duration in the 
study (ITT population). The PFS curve from the phase 3 trial of sorafenib for 
treatment of mRCC (TARGET) is shown for comparison [4]. 
CI, confidence interval; BID, twice daily; ITT, intent-to treat; PFS, progression-free survival; 
mRCC, metastatic renal cell carcinoma. 
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Figure 2. Maximum tumour shrinkage (% change from baseline in target lesions by 
independent assessment) according to the dose received for the longest duration in 
the study (ITT population)  
 
 
Dotted line represents the threshold for response using RECIST v1.0. 
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Supplementary materials 
Supplementary Table 1.Predefined dose modification levels for treatment with 
sorafenib 
Dose level -2 400 mg every-other-day 
Dose level -1 400 mg once-daily 
Dose level 1 400 mg twice-daily 
Dose level 2 600 mg twice-daily 
Dose level 3 800 mg twice-daily 
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Supplementary Table 2. Criteria for sorafenib dose delay and dose modification due 
to skin toxicities 
Toxicity grade 
During a course of 
therapy 
Dose for next cyclea  
Grade 1  Maintain dose level Maintain dose level 
Grade 2b 1st appearance 
Interrupt until resolved to 
grade 0/1  
Maintain dose level 
 2nd appearance 
Interrupt until resolved to 
grade 0/1 
Decrease by one dose level 
 3rd appearance 
Interrupt until resolved to 
grade 0/1 
Decrease by two dose levels 
 4th appearance 
Discontinue treatment 
permanently 
Discontinue treatment 
permanently 
Grade 3 1st appearance 
Interrupt until resolved to 
grade 0/1 
Decrease by one dose levelc 
 2nd appearance 
Interrupt until resolved to 
grade 0/1 
Decrease by two dose levels 
 3rd appearance 
Discontinue treatment 
permanently 
Discontinue treatment 
permanently 
aOne cycle = 28 days 
bThe investigator has the option of continuing therapy through a grade 2 skin toxicity 
with the exception of the following: hand–foot skin reaction, erythema multiforme; 
ulceration; wound complication. The investigator must follow the above criteria for 
subjects presenting with any of these skin toxicities.  
cFor subjects who require a dose reduction for grade 3 rash or hand–foot skin 
reaction, the dose may be increased to the starting dose after one full cycle (28 days) 
of therapy has been administered at the reduced dose without the appearance of 
rash or hand foot syndrome ≥ grade 1.  
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Supplementary Table 3. Management of treatment-emergent hypertension 
Grade of event (NCI-CTCAE v3)  Management/next dose 
Grade 1 asymptomatic and 
transient  
Consider increased BP monitoring  
Grade 2 asymptomatic and 
diastolic BP < 110 mm Hg  
Begin anti-hypertensive therapy and continue sorafenib  
 
Grade 2 symptomatic/ persistent  
or 
diastolic BP ≥ 110 mm Hg  
or 
Grade 3  
Sorafenib should be stoppeda until symptoms resolve 
and diastolic BP returns to ≤100 mm Hg. Treat subject 
with anti-hypertensives and when sorafenib is restarted, 
reduce by 1 dose levelb (refer to table 2)  
If diastolic BP not controlled to ≤100 mm Hg on therapy, 
reduce sorafenib by another dose level and monitor BP 
closelyc  
Grade 4 life-threatening  Discontinue protocol therapy  
BP, blood pressure; NIC-CTCAE, National Cancer Institute - Common Terminology 
Criteria for Adverse Events. 
Please note that specific criteria are not completely identical to NCI-CTCAE v3.  
aSubjects requiring a delay of >28 days should go off protocol therapy.  
bMay be able to resume full dose later.  
cSubjects requiring >2 dose reductions should go off protocol therapy. 
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Supplementary Table 4. Criteria for dose delay and dose modification due to 
heematologic AEs 
Grade  Dose delay Dose modification 
Grade 0–2 Treat on time No Change 
Grade 3 Treat on time Decrease one dose levelb 
Grade 4 Delaya until grade 2 Decrease one dose levelb 
aIf no recovery after 28 day delay, treatment will be discontinued unless subject is 
deriving clinical benefit 
bIf more than two dose reductions are required, treatment will be discontinued  
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Supplementary Table 5. Criteria for dose delay and dose modification due to non-
haematologic AEs (except skin toxicity)a 
Grade  Dose delay Dose modification 
Grade 0–2 Treat on time No change 
Grade 3 Delayb until grade 2 Decrease one dose level c 
Grade 4 
Discontinue protocol 
therapy 
Discontinue protocol therapy 
aAlso excludes nausea/vomiting that has not been pre medicated, and diarrhoea  
bIf no recovery after 28 day delay, treatment will be discontinued unless subject is 
deriving clinical benefit  
cIf no If more than 2 dose reductions are required, treatment will be discontinued  
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Supplementary Table 6. Reasons for permanent discontinuation of sorafenib, for 
patients in the ITT population who did not qualify for the mITT population by last dose 
received, n(%) 
 Overall 400 mg 
QOD 
400 mg 
once 
daily 
400 mg 
BID 
600 mg 
BID 
800 mg 
BID 
Adverse event 14 (28.6) 0 3 (6.1) 6 (12.2) 4 (8.2) 1 (2) 
Disease progression, 
recurrence or relapse 
32 (65.3) 1 (2) 4 (8.2) 10 (20.4) 4 (8.2) 9 (18.4) 
Othera 3 (6) 0 1 (2) 2 (4) 0 0 
BID, twice daily; ITT, intention-to-treat; mITT, modified ITT; QOD, every other day 
aOther reasons for discontinuation were recorded as one case each of: clinical endpoint 
reached; completed all planned treatments; and investigator decision, not protocol driven.  
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Supplementary Table 7. Pharmacokinetic parameters for sorafenib and its metabolites (M2, M4, and M5) after 28 days of twice daily dosing 
with sorafenib 400 mg, 600 mg or 800 mg BID (all patients valid for pharmacokinetics) 
Parameter 
400 mg BID 600 mg BID 800 mg BID 
n 
Geometric 
meana 
%CVa n 
Geometric 
meana 
%CVa n 
Geometric 
meana 
%CVa 
Sorafenib 
AUC(0–8)ss (mg·h/L) 40 40.61 39.5 30 41.84 43.5 28 36.19 45.1 
AUC(0–10)ss (mg·h/L) 40 49.98 39.2 30 51.24 43.7 26 43.83 47.8 
AUC(0–12)ss (mg·h/L) 32 57.18 39.1 23 57.56 46.1 19 46.98 51.9 
Cmax (mg/L) 40 7.53 38.0 31 7.62 39.3 28 6.64 42.1 
tmax (h) 40 2.0 (0–12.0) 31 2.0 (0–12.0) 28 2.0 (0–12.0) 
 
 
        Metabolite M2 
AUC(0–8)ss (mg·h/L) 40 7.11 75.4 30 8.39 82.7 28 6.99 89.4 
AUC(0–10)ss (mg·h/L) 40 8.80 74.3 30 10.36 82.1 27 8.23 87.2 
AUC(0–12)ss (mg·h/L) 32 9.58 78.2 23 11.24 75.9 20 8.41 94.6 
Cmax (mg/L) 40 1.31 80.8 31 1.51 81.4 28 1.30 88.5 
tmax (h) 40 2.0 (0–10.3) 31 2.0 (0–12.0) 28 1.0 (0–12.0) 
          Metabolite M4 
AUC(0–8)ss (mg·h/L) 40 2.5 81.4 30 2.44 87.0 28 1.88 80.8 
AUC(0–10)ss (mg·h/L) 40 3.1 80.8 30 3.04 86.5 27 2.22 77.2 
AUC(0–12)ss (mg·h/L) 32 3.33 77.2 23 3.25 77.8 20 2.39 83.5 
Cmax (mg/L) 40 0.48 90.1 31 0.47 88.0 28 0.36 82.8 
tmax (h) 40 0 (0–10.1) 31 2.0 (0–12.0) 28 2.0 (0–12.0) 
          Metabolite M5 
AUC(0–8)ss (mg·h/L) 40 2.13 141.3 30 2.77 140.8 28 2.65 147.9 
AUC(0–10)ss (mg·h/L) 40 2.65 139.5 30 3.44 141.5 27 3.03 137.0 
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Parameter 
400 mg BID 600 mg BID 800 mg BID 
n 
Geometric 
meana 
%CVa n 
Geometric 
meana 
%CVa n 
Geometric 
meana 
%CVa 
AUC(0–12)ss (mg·h/L) 31 3.03 117.6 23 3.55 135.5 20 3.19 162.2 
Cmax (mg/L) 40 0.40 144.6 31 0.52 136.6 28 0.49 145.0 
tmax (h) 40 0 (0–12.0) 31 2.0 (0–12.0) 28 0 (0–12.0) 
aExcept tmax, for which median and range are presented. 
AUC(0–X)ss, area under the curve from time 0 to X hours post-dose at steady state; BID, twice daily; Cmax, maximum plasma concentration; CV, coefficient of 
variation; ss, steady state; tmax, time to maximum plasma concentration. 
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Supplementary Figure 1. Patient flow  
 
 
* Efficacy evaluated every two cycles. 
 
